Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 9/20 | 0.57 |
| ▸ | EGFR | P00533 | 3/20 | 0.55 |
| ▸ | ITK | Q08881 | 3/20 | 0.55 |
| ▸ | AURKA | O14965 | 6/20 | 0.53 |
| ▸ | BCL6 | P41182 | 1/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.49 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.49 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.49 |
| ▸ | CDC7 | O00311 | 1/20 | 0.49 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.49 |
| ▸ | PLK4 | O00444 | 1/20 | 0.49 |
| ▸ | STK25 | O00506 | 1/20 | 0.49 |
| ▸ | CIT | O14578 | 1/20 | 0.49 |
| ▸ | RIOK3 | O14730 | 1/20 | 0.49 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.49 |
| ▸ | IKBKB | O14920 | 1/20 | 0.49 |
| ▸ | GAK | O14976 | 1/20 | 0.49 |
| ▸ | CHUK | O15111 | 1/20 | 0.49 |
| ▸ | MUSK | O15146 | 1/20 | 0.49 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1222074 | 0.92 | EGFR (0.65) | SYKEGFRITKAURKABCL6 | |
| SCHEMBL1222060 | 0.90 | SYK (0.54) | SYKEGFRITKAURKAADORA3 | |
| SCHEMBL1221693 | 0.88 | SYK (0.64) | SYKEGFRITKAURKAADORA3 | |
| SCHEMBL1222077 | 0.88 | SYK (0.53) | SYKEGFRITKAURKABCL6 | |
| SCHEMBL12894667 | 0.87 | SYK (0.62) | SYKEGFRITKAURKAADORA3 | |
| SCHEMBL1222117 | 0.86 | SYK (0.57) | SYKEGFRITKAURKABCL6 | |
| SCHEMBL1222410 | 0.85 | SYK (0.58) | SYKEGFRITKAURKAADORA3 | |
| SCHEMBL1040295 | 0.85 | SYK (0.55) | SYKEGFRITKAURKAADORA3 | |
| SCHEMBL1035455 | 0.83 | SYK (0.58) | SYKEGFRITKAURKAADORA3 | |
| SCHEMBL1037441 | 0.83 | SYK (0.56) | SYKEGFRITKAURKAADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110028405-A1 | SULFAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2011-02-03 | — | — | US | claimed |
| EP-2234986-A2 | SULFAMIDES AS ZAP-70 INHIBITORS | Cellzome Limited (GB) | 2010-10-06 | — | — | EP | claimed |
| WO-2009080638-A2 | SULFAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2009-07-02 | — | — | WO | claimed |
| US-20110028405-A1 | SULFAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2011-02-03 | — | — | US | disclosed |
| US-20110028405-A1 | SULFAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2011-02-03 | — | — | US | disclosed |
| EP-2234986-A2 | SULFAMIDES AS ZAP-70 INHIBITORS | Cellzome Limited (GB) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009080638-A2 | SULFAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2009-07-02 | — | — | WO | disclosed |
| WO-2009080638-A2 | SULFAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028405-A1 | SULFAMIDES AS ZAP-70 INHIBITORS | ZAP70, SYK, LCK | SYK 2/4885EGFR 2202/4885ITK 693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.